JP6944148B2 - リパーゼ阻害剤 - Google Patents
リパーゼ阻害剤 Download PDFInfo
- Publication number
- JP6944148B2 JP6944148B2 JP2017064578A JP2017064578A JP6944148B2 JP 6944148 B2 JP6944148 B2 JP 6944148B2 JP 2017064578 A JP2017064578 A JP 2017064578A JP 2017064578 A JP2017064578 A JP 2017064578A JP 6944148 B2 JP6944148 B2 JP 6944148B2
- Authority
- JP
- Japan
- Prior art keywords
- lipase
- composition
- extract
- plant
- lipase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940086609 Lipase inhibitor Drugs 0.000 title claims description 29
- 239000000203 mixture Substances 0.000 claims description 52
- 241000196324 Embryophyta Species 0.000 claims description 30
- 230000002401 inhibitory effect Effects 0.000 claims description 29
- 239000000284 extract Substances 0.000 claims description 28
- 235000013305 food Nutrition 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000002537 cosmetic Substances 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 13
- 240000001490 Stauntonia hexaphylla Species 0.000 claims description 12
- 235000014570 Stauntonia hexaphylla Nutrition 0.000 claims description 12
- 240000008027 Akebia quinata Species 0.000 claims description 11
- 235000007756 Akebia quinata Nutrition 0.000 claims description 11
- 244000036770 Akebia trifoliata Species 0.000 claims description 11
- 235000012980 Akebia trifoliata Nutrition 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 11
- 239000000654 additive Substances 0.000 claims description 5
- 230000000996 additive effect Effects 0.000 claims description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000003579 anti-obesity Effects 0.000 claims 1
- 239000000469 ethanolic extract Substances 0.000 claims 1
- 230000006372 lipid accumulation Effects 0.000 claims 1
- 108090001060 Lipase Proteins 0.000 description 40
- 102000004882 Lipase Human genes 0.000 description 40
- 239000004367 Lipase Substances 0.000 description 38
- 235000019421 lipase Nutrition 0.000 description 38
- 229940040461 lipase Drugs 0.000 description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 239000000419 plant extract Substances 0.000 description 19
- 238000000605 extraction Methods 0.000 description 18
- 239000003925 fat Substances 0.000 description 13
- 102000019280 Pancreatic lipases Human genes 0.000 description 11
- 108050006759 Pancreatic lipases Proteins 0.000 description 11
- 235000014113 dietary fatty acids Nutrition 0.000 description 11
- 229930195729 fatty acid Natural products 0.000 description 11
- 239000000194 fatty acid Substances 0.000 description 11
- 150000004665 fatty acids Chemical class 0.000 description 11
- 229940116369 pancreatic lipase Drugs 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 108010079522 solysime Proteins 0.000 description 9
- 208000008589 Obesity Diseases 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- 235000020824 obesity Nutrition 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241000722953 Akebia Species 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- 241001083838 Lardizabalaceae Species 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 239000002798 polar solvent Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 229940127470 Lipase Inhibitors Drugs 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 235000019577 caloric intake Nutrition 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 235000019626 lipase activity Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000012454 non-polar solvent Substances 0.000 description 4
- 244000005714 skin microbiome Species 0.000 description 4
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000133425 Stauntonia Species 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000004042 decolorization Methods 0.000 description 3
- 238000004332 deodorization Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 241000787962 Akebia x pentaphylla Species 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000208688 Eucommia Species 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 239000012901 Milli-Q water Substances 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- -1 auxiliaries Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229940122601 Esterase inhibitor Drugs 0.000 description 1
- 241000208689 Eucommia ulmoides Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 241000191936 Micrococcus sp. Species 0.000 description 1
- 241000235403 Rhizomucor miehei Species 0.000 description 1
- 240000005384 Rhizopus oryzae Species 0.000 description 1
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000179532 [Candida] cylindracea Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 1
- 229960001051 dimercaprol Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 150000002759 monoacylglycerols Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 125000003203 triacylglycerol group Chemical group 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Description
(I−1)アケビ科に属する植物の葉の溶媒抽出物を有効成分とするリパーゼ阻害剤。
(I−2)上記アケビ科に属する植物がアケビ属及びムベ属に属する植物から選択される少なくとも1種である、(I−1)に記載するリパーゼ阻害剤。
(I−3)アケビ属に属する植物がアケビ(Akebia quinata (Thunb. ex Houtt.) Decne.)、ゴヨウアケビ(Akebia x pentaphylla (Makino) Makino)およびミツバアケビ(Akebia trifoliata (Thunb.) Koidz. subsp. trifoliata)、好ましくはアケビ(Akebia quinata (Thunb. ex Houtt.) Decne.)であり、ムベ属に属する植物がムベ(Stauntonia hexaphylla (Thunb.) Decne.)である(I−2)に記載するリパーゼ阻害剤。
(I−4)上記溶媒が水である(I−1)乃至(I−3)のいずれかに記載するリパーゼ阻害剤。
(I−5)飲食品組成物、医薬品組成物、医薬部外品組成物、化粧品組成物またはこれらの組成物の添加剤である、(I−1)乃至(I−4)のいずれかに記載するリパーゼ阻害剤。
本発明のリパーゼ阻害剤は、アケビ科に属する植物の葉の溶媒抽出物を有効成分とする。
(1)植物乾燥粉末の調製
各種植物の部位(アケビ葉、ムベ葉)を採取し水洗した後、全自動洗濯機(National NA-F50Y2)を用いて脱水し、−30℃で冷凍した。この冷凍品を25℃で72時間、凍結乾燥((株)アルバック製真空凍結乾燥機(DF-03H)使用)し、乾燥後の試料を粉砕機((株)CMT製のVIBRATING SAMPLE MILL TI-100)を用いて微粉砕して、植物乾燥粉末を調製した。
上記微粉砕して調製した試料(植物乾燥粉末)1gに沸騰したミリQ水10mlを加え、沸騰湯浴中で30分間加温(ほぼ100℃)抽出した後、抽出液を急冷し、濾紙(No.2)を用いて濾過して、濾液を植物部位の熱水抽出液として回収した。回収した濾液(熱水抽出液)をロータリーエバポレーターで減圧濃縮した後、濃縮液を凍結乾燥して、植物抽出物(乾燥エキス)を得た。これらの植物抽出物(乾燥エキス)10mgあたり1mlの割合でミリQ水を加えて溶解し、植物エキス(濃縮還元物:10mg/ml)を調製した。これらの各植物エキスを用いて、以下のリパーゼ阻害活性試験を行った。
各植物エキスのリパーゼ阻害活性を、リパーゼ(SIGMA社製ブタ膵リパーゼ:Lipase from porcine pamcreas,Type II)およびリパーゼキットS(DSファーマバイオメディカル(株)製)を用いて測定した。測定方法は、製造者の説明書に従った。
試験管に、実験例1で調製した各植物エキス(実施例1〜2)、並びにそれらを倍々希釈して32倍希釈まで調製した植物エキス希釈液(以上、「被験試料」)各25μlを入れ、0.05mg/mlに調製したリパーゼ水溶液40μlを加え、発色液(5,5’-ジチオビス[2-ニトロ安息香酸])500μlとエステラーゼ阻害液(フェニルメチルスルホニルフルオリド)10μlを加えて、30℃で5分間反応させた。その後、基質液(三酪酸ジメルカプロール、ドデシル硫酸ナトリウム)50μlをそれぞれに加え混和し、30℃で30分間反応させた後、反応停止液1mlを加えた。この反応液(被験試料反応液)250μlを96穴プレートに採取し、分光光度計(PerkinElmer社製Enspire/2300)で410nmの吸光度を測定した。またコントロールとして、上記被験試料の代わりに抽出溶媒(ミリQ水)を用いて、上記と同様に反応させて410nmの吸光度(コントロールの吸光度)を測定した。
リパーゼ阻害率(%)={1−(S−SB)/(C−CB)}×100
S:被験試料反応液の吸光度
SB:被験試料ブランク(被験試料そのもの)の吸光度
C:コントロールの吸光度
CB:コントロールブランク(抽出溶媒そのもの)の吸光度
Claims (3)
- アケビ、ゴヨウアケビ、ミツバアケビ、及びムベから選ばれる少なくとも1種の植物の葉の溶媒抽出物を有効成分とするリパーゼ阻害剤
〔但し、下記を除く:
ムベ(Stauntonia Hexaphylla)抽出物を有効成分として含む抗炎組成物、
並びに
アケビ(Akebia quinata D.)葉の80%エタノール抽出物を有効成分とする抗肥満組成物、及び脂質蓄積抑制組成物。〕。 - 上記溶媒が水である請求項1に記載するリパーゼ阻害剤。
- 飲食品組成物、医薬品組成物、医薬部外品組成物、化粧品組成物またはこれらの組成物の添加剤である、請求項1又は2に記載するリパーゼ阻害剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017064578A JP6944148B2 (ja) | 2017-03-29 | 2017-03-29 | リパーゼ阻害剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017064578A JP6944148B2 (ja) | 2017-03-29 | 2017-03-29 | リパーゼ阻害剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018168076A JP2018168076A (ja) | 2018-11-01 |
JP6944148B2 true JP6944148B2 (ja) | 2021-10-06 |
Family
ID=64019327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017064578A Active JP6944148B2 (ja) | 2017-03-29 | 2017-03-29 | リパーゼ阻害剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6944148B2 (ja) |
-
2017
- 2017-03-29 JP JP2017064578A patent/JP6944148B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2018168076A (ja) | 2018-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101930483B1 (ko) | 발효 청미래덩굴 잎 및 이의 추출물 | |
JP4074652B1 (ja) | カテキン誘導体の製造方法 | |
JP2009001515A (ja) | エストロゲン調節作用を有するイソフラボン誘導体、それからなる食品製剤、化粧品、子宮内膜症治療薬 | |
JP2011201788A (ja) | 抗炎症剤 | |
JP2006347952A (ja) | リパーゼ活性化作用を呈するアントラキノン誘導体、それからなる抗肥満薬、食品製剤及び化粧品 | |
JP2013198444A (ja) | 長命草及び魚介油を含む組成物 | |
JP4979184B2 (ja) | 杜仲葉水抽出成分を含むリパーゼ阻害剤 | |
JP2018168144A (ja) | リパーゼ阻害剤、及びその利用 | |
JP2010280734A (ja) | リパーゼ阻害活性且つ抗酸化性を有する抗肥満剤 | |
JP2008285420A (ja) | クロロゲン酸酵素処理物の製造方法及びヒアルロニダーゼ阻害剤 | |
JP6944148B2 (ja) | リパーゼ阻害剤 | |
KR20190136769A (ko) | 백산차 추출물의 분획물을 유효성분으로 함유하는 항산화 및 항염증용 조성물 | |
KR20220048640A (ko) | 항염증 면역활성 및 항산화 활성을 가지며, 노인의 근력 또는 근육 강화를 위한 근세포 조성에 우수한 효과를 제공하는 프테로카리아 스테놉테라 추출물을 포함하는 화장료 조성물, 약학적 조성물, 및 식품 조성물 | |
JP2012136447A (ja) | リパーゼ阻害剤並びにそれを含有する化粧料、飲食品組成物及び医薬品組成物 | |
WO2019131274A1 (ja) | 緑茶抽出物由来の発酵物の製造方法及び緑茶抽出物由来の麹発酵物 | |
JP2007204447A (ja) | 中性脂肪減少作用を呈するカルニチン誘導体、それからなる抗肥満薬、食品製剤及びセルライト減少作用を呈する化粧品 | |
JP2009249331A (ja) | 植物由来の高脂血症の予防または改善剤 | |
JP4666736B2 (ja) | 高血圧症予防・改善・治療剤 | |
JP2009185004A (ja) | メタボリック・シンドローム改善剤 | |
JP5085198B2 (ja) | 抗酸化剤 | |
JP2009001514A (ja) | 炎症性サイトカイン産生抑制作用を有するアネトール誘導体、それからなる食品製剤、化粧品、抗炎症剤 | |
JP2005089385A (ja) | リポキシゲナーゼ阻害剤 | |
JP2007015943A (ja) | メラニン生成抑制剤 | |
JP2007099715A (ja) | 中性脂肪減少作用を呈するアリイン脂肪酸結合体、それからなる食品製剤、化粧品及び抗肥満剤 | |
KR102117547B1 (ko) | 필레아 마티니 추출물을 포함하는 염증성 질환 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200304 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210316 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210422 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210803 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210901 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6944148 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |